文献速递神经肿瘤脊柱脊髓外科

髓内脊髓转移性肾细胞癌:疾病表现、治疗与预后的系统综述并附病例示例

Intramedullary Spinal Metastatic Renal Cell Carcinoma: Systematic Review of Disease Presentation, Treatment, and Prognosis with Case Illustration.
PubMed 文献 · World Neurosurg · 2019-11-14

本文按PRISMA指南系统检索PubMed,纳入仅人类髓内肾细胞癌转移的临床报告,共23篇报告31例患者,并附本机构治疗的一例示例。47%肿瘤位于颈段,41%伴脑转移;肢体无力(72%)、尿失禁(41%)、感觉异常(47%)、局部脊柱疼痛(38%)最常见。单纯手术占34%,手术联合放疗占31%,单纯放疗占25%;肾细胞癌诊断后平均32.1个月检出脊髓转移,此后平均生存8个月(范围0-65个月)。

要点

  • 31例中47%位于颈段,41%伴脑转移,肢体无力(72%)为最常见症状。
  • 单纯手术34%、手术联合放疗31%、单纯放疗25%,为最主要的三种治疗方式。
  • 肾细胞癌诊断后平均32.1个月检出脊髓转移,此后平均生存8个月(范围0-65个月)。

核心结论

  • 髓内脊髓转移性肾细胞癌罕见且可导致严重神经功能损害,生存似受治疗方式影响,也可能受疾病发现时所处分期影响。

研究设计与样本

  • 按PRISMA指南系统检索PubMed电子数据库,仅纳入人类髓内肾细胞癌转移的临床报告,共23篇报告、31例患者;另附本机构治疗的一例示例。

主要发现

  • 47%的肿瘤位于颈段,41%的病例存在脑转移。
  • 最常见症状为肢体无力(72%)、尿失禁(41%)、感觉异常(47%)和局部脊柱疼痛(38%)。
  • 治疗方式为单纯手术切除34%、手术联合放疗31%、单纯放疗25%。
  • 脊髓转移在肾细胞癌诊断后平均32.1个月检出,此后患者平均生存8个月(范围0-65个月)。
  • 报告的手术后生存为9.1个月,单纯放疗后为11.2个月,联合治疗为5个月,放疗后生存似最长。

临床怎么用

  • 作者指出髓内脊髓转移性肾细胞癌罕见且神经功能损害严重,未来类似情形的处理可参考本文综述与示例病例。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Renal cell carcinoma (RCC) metastases to the intramedullary spinal cord carry a grim prognosis. The purpose of this review is to provide the reader with a comprehensive and systematic review of the current literature, and to present an illustrative case that would aid in the future management of similar scenarios. METHODS: A systematic review of the literature using the PubMed electronic database was made according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Only human clinical reports of intramedullary RCC metastasis were included. We also present an illustrative case that was treated at our institution. RESULTS: We identified 23 reports with a total of 31 patients. Of the tumors, 47% were located at the cervical level. Brain metastases were present in 41% of cases. Limb weakness (72%), urinary incontinence (41%), dysesthesia (47%), and localized spinal pain (38%) were the most frequently reported symptoms. Surgical resection alone was used in 34% of cases, followed by a combination of surgery and radiotherapy (31%), and radiotherapy alone (25%). Spinal metastases were detected an average of 32.1 months after the diagnosis of RCC, and mean patient survival after that was 8 months (range, 0-65 months). Reported survival after radiotherapy appeared to be the longest (11.2 months) compared with surgery (9.1 months) and combination therapy (5 months). CONCLUSIONS: Intramedullary spinal metastatic RCC is a rare entity with debilitating neurologic potential. Survival appears to be affected by the treatment method but is also likely influenced by the stage of discovery of the disease.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Barrie U, Elguindy M, Pernik M, et al. Intramedullary Spinal Metastatic Renal Cell Carcinoma: Systematic Review of Disease Presentation, Treatment, and Prognosis with Case Illustration. World Neurosurg. 2019. PMID: 31734421. doi:10.1016/j.wneu.2019.11.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。